No Data
No Data
Design Therapeutics Inc (DSGN) Q1 2024 Earnings: A Detailed Financial and Strategic Review
Hold Rating Maintained for Design Therapeutics Amid Strategic Updates and Financial Review
RBC Capital Reaffirms Their Hold Rating on Design Therapeutics (DSGN)
Design Therapeutics Q1 EPS $(0.20) Beats $(0.29) Estimate
Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.29) by 31.03 percent. This is a 42.86 percent increase over losses of
Express News | Design Therapeutics Inc - Qtrly Shr Loss $0.20
Design Therapeutics | 10-Q: Quarterly report
No Data